Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma
- PMID: 38627894
- DOI: 10.1111/ijlh.14284
Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma
References
REFERENCES
-
- Ruinemans‐Koerts J, Verkroost C, Schmidt‐Hieltjes Y, et al. Interference of therapeutic monoclonal immunoglobulins in the investigation of M‐proteins. Clin. Chem. Lab. Med. 2014;52:e235‐e237. doi:10.1515/cclm‐2013‐0898
-
- Moore LM, Cho S, Thoren KL. MALDI‐TOF mass spectrometry distinguishes daratumumab from M‐proteins. Clin Chim Acta. 2019;492:91‐94. doi:10.1016/j.cca.2019.02.017
-
- McCudden CR, Jacobs JFM, Keren D, Caillon H, Dejoie T, Andersen K. Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. Clin Biochem. 2018;51:72‐79. doi:10.1016/j.clinbiochem.2017.08.013
-
- Willrich MAV, Ladwig PM, Andreguetto BD, et al. Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation. Clin Chem Lab Med. 2016;54:1085‐1093. doi:10.1515/cclm‐2015‐1023
-
- Genzen JR, Kawaguchi KR, Furman RR. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. Br J Haematol. 2011;155:123‐125. doi:10.1111/j.1365‐2141.2011.08644.x
Publication types
LinkOut - more resources
Full Text Sources